Webinar: Pioneering the Next Era of Spatial Biology with MERFISH 2.0 and the MERSCOPE Ultra™ Platform

28 May 2025 | Wednesday | 60 Minutes
San Francisco 08:00 | London 16:00 | Paris 17:00 | Singapore 23:00 

VIEW AGENDA

High-plex spatial transcriptomics has transformed biological discovery by revealing the intricate gene expression landscapes of tissues at single-cell resolution. However, FFPE-preserved samples—common in clinical and archival biobanks—have historically posed significant limitations due to RNA degradation and crosslinking. In this webinar, we bring together two experts to explore how Vizgen’s groundbreaking MERFISH 2.0 chemistry and the MERSCOPE Ultra™ Platform are redefining the possibilities of spatial genomics across both technical and translational research.

Learning Objectives:

• Understand the challenges of spatial transcriptomics in FFPE tissues and how MERFISH 2.0 overcomes degraded RNA and sample fragmentation.
• Explore the technical innovations of MERFISH 2.0 chemistry and sample prep, including how it enables profiling of up to 1,000 genes in tissue sections up to 3 cm².
• Discover real-world applications of MERFISH 2.0 on the MERSCOPE Ultra™ Platform, and how it empowers spatial genomics using clinical and archived tissue samples for translational research.

Join us to learn how cutting-edge spatial technology from Vizgen is unlocking the potential of previously inaccessible tissue samples and catalyzing breakthroughs in both basic science and translational medicine.

Event structure:

40 Minutes Presentation & 20 Minutes Q&A

Presenter, Duration & Presentation snapshot

• Alex Genshaft (10 min), will introduce MERFISH 2.0 chemistry and an optimized workflow, now implemented on the MERSCOPE Ultra™ Platform, which enables robust transcript detection in FFPE tissues.
• Mark Watson (30 min), will present breast cancer datasets generated using MERFISH 2.0, offering a compelling example of how spatial genomics is accelerating our understanding of histologically complex ‘triple-negative’ breast cancer toward the discovery of novel prognostic biomarkers that better inform personalized cancer treatment strategies.
• Q&A session – 15-20 min

Sponsored by: